Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 42 for “"Pharmacogenomics"”.
-
Development of genotyping systems for pharmacogenomics profiling
Genetic variability in genes encoding drug metabolizing enzymes, transporters and targets are known to be the main factors of inter-individual differences in therapeutic outcome. Genetic factors are estimated to be responsible for about 15-30% of inter-individual variation in drug disposition and …
-
PHARMACOGENOMICS OF OPIOID RESPONSE IN EUROPEAN ADVANCED CANCER PATIENTS
… They represent the starting point for further pharmacogenomics studies of opioid therapy in larger sample sizes, which might be more representative of the whole population. This study provides new insights into the genetic factors influencing pain intensity suggesting new potential markers of …
-
Personalized Medicine: Studies of Pharmacogenomics in Yeast and Cancer
… specificity in predictive modeling of cancer pharmacogenomics. The two complementary algorithms highlight the challenges faced in personalized medicine and the potential solutions. This thesis detailed the results and analysis that demonstrate the importance of causality and context …
-
Pharmacogenomics of warfarin: comprehensive evaluation of important warfarin genomic response factors
Introduction: Warfarin is the most widely prescribed anticoagulant for the prevention and treatment of thromboembolic diseases. However, warfarin use is complicated by its narrow therapeutic range and inter-individual variability in the starting dose required to achieve a stable international …
-
Nonparametric variable selection and dimension reduction methods and their applications in pharmacogenomics
… of samples is several hundreds to thousands. Pharmacogenomics is an example of genomics data analysis that we are considering here. Pharmacogenomics research uses whole-genome genetic information to predict individuals' drug response. Because whole-genome data are high dimensional and their …
-
Pharmacogenomics and pharmacokinetics of dolutegravir and tenofovir in Southern Africans living with HIV
Background The World Health Organization (WHO) recommends dolutegravir in combination with a nucleos(t)ide reverse transcriptase inhibitor (NRTI) backbone as the preferred first-line regimen for people living with HIV (PLWHIV) initiating antiretroviral therapy (ART). Tenofovir alafenamide (TAF) and …
-
The aetiopathogenesis, cardiovascular and metabolic complications, and pharmacogenomics of Addison's disease in South Africa
This thesis aimed to address a number of unanswered research questions in Addison's Disease: investigate whether autoimmunity is the predominant cause of Addison's disease in South Africa and if a human leukocyte (HLA) DQ antigen association exists; the extent to which lipids, lipoproteins and …
-
Pharmacogenomics and pharmacokinetics of antiretroviral drugs and their associations with metabolic complications in HIV-infected Black South Africans
BACKGROUND: Antiretroviral therapy (ART), notably efavirenz and lopinavir, have been associated with metabolic abnormalities known to increase cardiovascular risk. Efavirenz and lopinavir pharmacokinetics demonstrate considerable interindividual variability, which in part, may be explained by host …
-
The Parallax of Personalized Medicine: A Critical, Socio-Medical Analysis of the Trajectory of Pharmacogenomics and Genome Wide Association Studies
… based scientific and medical processes like pharmacogenomics and Genome Wide Association Studies (GWAS) may further perpetuate medical inequity, health disparities, and discrimination. Thus, it is important that we (in the medical community) acknowledge and delegitimize the use of race and …
-
Involvement of microRNAs and their targeted genes in the pharmacogenomics of lithium response in bipolar disorder: a genome wide study
Bipolar disorder (BD) is a frequent mood disorder characterized by manic and depressive episodes. The disease affects approximately 1-2% of the population. Lithium is a mood stabilizer used as first line treatment of BD episodes and for maintenance. Despite 30% of patients show full remission of …
-
Pharmacogenomics of sickle cell disease therapeutics: pain and drug metabolism associated gene variants and hydroxyurea-induced post-transcriptional expression of miRNAs
… of drugs and there is a limited data on pharmacogenomics of SCD therapeutics. Vaso-occlusive crisis (VOC) are the main clinical events of SCD and are associated with recurrent and long-term use of antalgics/opioids and HU. This project aimed to investigate the clinical and genetic …
-
Exploring the role of mu opioid receptor (OPRM1) and CYP2B6 gene variations for methadone pharmacogenomics. Can these variations be used to advance toxicological interpretation post-mortem?.
Methadone is increasingly involved in drug overdose cases and the molecular actions of the drug in vivo are largely unknown requiring elucidation. This study set out to examine the relationship between methadone toxicity and CYP2B6 and mu (μ) opioid receptor (OPRM1) single nucleotide polymorphisms …
-
Computational analysis of cis-regulatory mechanisms underlying cellular response to drug perturbations
… two seemingly disparate subfields of biology: pharmacogenomics and regulatory genomics. The former concentrates on how inherited factors such as SNPs and genes inform the response to medical interventions designed to ameliorate disease states, processes, and phenotypes; ontologically, it …
-
Using machine learning to understand the link between gene essentiality, gene expression and the chemosensitivity of cancer cells
The emergence of pharmacogenomics databases has presented unique opportunities to leverage machine learning in precision medicine, particularly in drug response prediction. In this thesis, an in-depth investigation is conducted on carefully curated and integrated breast cancer focused datasets from …
-
Pharmacogenetics of stavundine : role of genetic variation in mitochondrial DNA and polymerase gamma among adult Malawian HIV/AIDS patients
… tools and drugs developed on the basis of pharmacogenomics knowledge. In an effort to contribute to this knowledge, the role of variation in mitochondrial DNA (mtDNA) and polymerase gamma (POL-γ) on how patients respond to stavudine-containing antiretroviral therapy (ART) among adult …
-
The role of warfarin pharmacogenomics on the time it takes to reach stable therapeutic International Normalized Ratio (INR) and on warfarin dose required to maintain stable therapeutic INR in Black African and Mixed Ancestry South Africans: a focus on CYP2C9 and VKORC1
… develop personalized algorithms which integrate pharmacogenomics to assist with effective warfarin dosing and prevention of warfarin related complications is to be realized.
-
Novel Immunometabolic Therapies and Prognostic Markers for Lymphedema
… lymphedema. Using both mechanism of action- and pharmacogenomics-based approaches, drugs candidates were identified to target IL-17 and/or PPAR gene expression, and reduced lymphedema fibrosis in cellular and animal models. Additionally, in a prognostic biomarker study of 373 breast cancer …
-
Pharmacometric modelling to inform and improve TB and HIV treatment: Focus on drug-drug interactions and neglected populations
… from patients with TB or/and HIV. We analyse the pharmacogenomics, pharmacokinetics, and drug-drug interaction of efavirenz, isoniazid, and bedaquiline in pregnant women and characterise the pharmacokinetics and pharmacodynamics of high dose isoniazid in adults with multidrugresistant …
-
LINKING TRANSCRIPTIONAL AND MORPHOLOGICAL HETEROGENEITY TO THERAPEUTIC VULNERABILITIES IN GLIOBLASTOMA
… designed an analytical framework that integrates pharmacogenomics and CRISPR genome-editing with single cell RNA sequencing (scRNA-seq) data, leveraging the Cancer 13Dependency Map (DEPMAP) resource. This framework aims to prioritize GBM subtypes’ vulnerabilities upon a broad spectrum of genetics …
-
Payer Perspectives On Preemptive Pharmacogenetic Testing
… Implementation Consortium (CPIC) and the Pharmacogenomics Research Network (PGRN) was viefavorably. However, this would not drive policy decisions. Negative opinions came from a concern of the lack of data that would make these tests actionable for a payer from a policy development point …
Page 1 of 3